What If We Could Test Depression Drugs Before Patients Take Them? Dr Talia Cohen Solal - NeuroKaire

0:00-29:19

In this episode of Diagnosing Dx, David Filby is joined by Talia Cohen Solal, CEO at NeuroKaire. Talia is a neuroscientist by training who spent more than a decade in academia, including time at Oxford, UCL, and Columbia, before moving into the startup world to get closer to real patient impact. In this conversation, we explore why precision medicine has transformed fields like oncology but still has so far to go in psychiatry, and how NeuroKaire is trying to change that. We discuss the limits of current antidepressant prescribing and how NeuroKaire is using patient-derived neurons to predict which treatments are most likely to work for each individual. This is a practical conversation about precision psychiatry, commercialization, clinical evidence, and what it takes to bring better mental health diagnostics into real patient care.

Publisher

Diagnosing Dx

Published

July 7, 2026

Duration

29 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

Elevra Consulting

DD

Diagnosing Dx

@diagnosingdx

#testdepressiondrugs #drtaliacohen #neurokaire #lifesciences

The Nile